Allogene Therapeutics, Inc. Common Stock

ALLONASDAQ • USD
0.83 USD
↘ 0.01 (1.16%)🟢PRE MARKET (AS OF 04:01 AM EST)
🟢Market: OPEN

Allogene Therapeutics, Inc. Common Stock (ALLO) trades at $0.83 per share. Both sides of the analysis point lower: technicals flash "Strong Sell" and fundamentals confirm with a "Sell" reading. This is driven by a concerning Altman Z-Score in the distress zone, a weak Piotroski F-Score of 0/9, negative Return on Equity, a bearish Death Cross on the long-term moving averages and bearish long-term moving average alignment. On valuation, ALLO trades roughly in line with sector averages — neither particularly cheap nor expensive.

Technical & fundamental data as of Nov 13, 2026.

Open?$0.83
High?$0.83
Low?$0.83
Prev. Close?$0.84
Volume?1
Avg. Volume?9.7M
VWAP?$0.83
Rel. Volume?0.00x
Bid / Ask
Bid?$0.72 × 100
Ask?$0.96 × 100
Spread?$0.24
Midpoint?$0.84
Valuation & Ratios
Market Cap?291.0M
Shares Out?346.5M
Float?274.9M
Float %?79.6%
P/E Ratio?N/A
P/B Ratio?0.74
EPS?-$0.50
Dividend?0.00%
Ex-Dividend?N/A
News
Profile
Allogene Therapeutics Inc is a clinical stage immuno-oncology company pioneering the development of genetically engineered allogeneic T cell product candidates for the treatment of cancer and autoimmune diseases. Its pipeline includes "off-the-shelf" T cell candidates designed to target cancer cells or eliminate autoreactive cells in patients with autoimmune disorders. Its three core programs are: Large B-Cell Lymphoma (LBCL), Autoimmune Disease (AID) and Renal Cell Carcinoma (RCC).
Employees
152
Market Cap
290.6M
Industry
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)
Listed
2018-10-11
Address
210 EAST GRAND AVENUE
SOUTH SAN FRANCISCO, CA 94080
Phone: (650) 457-2700
Technical OutlookStrong Sell
Strong SellNeutralStrong Buy
Long-Term (Tide)?▼ Bearish(-3/3)
Medium-Term (Wave)?▼ Bearish(-2/3)
Short-Term (Ripple)?▼ Bearish(-2/3)
MA Alignment?Bearish Alignment
Full Technical Analysis →
Fundamental OutlookSell
Strong SellNeutralStrong Buy
F-Score?
3
Z-Score?
0
Momentum?
50
Short Sent.?
45
Piotroski F-Score?0/9Weak
Altman Z-Score?-5.01Distress
Confidence?59%Low
Full Fundamental Analysis →
Short InterestHigh
Short % of Float?18.66%High
Short Interest?51.3M
Days to Cover?6.2
Free Float274.9M
Avg Daily Volume8.3M
Settlement Date2026-10-30
Financial Health
Current Ratio?7.79Strong
Quick Ratio?7.79Strong
Cash Ratio?0.76Adequate
Debt/Equity?0.00Low
ValuationFAIRLY VALUEDvs 1 peers + S&P 500
Score
67/100
P/E?
N/A▾
P/B?
Peers
100
S&P
97
0.74CHEAP▾
P/S?
Peers
100
S&P
3
62.72HIGH▾
P/FCF?
N/A▾
EV/EBITDA?
S&P
97
-1.5CHEAP▾
EV/Sales?
Peers
100
S&P
3
56.41HIGH▾
Returns & Efficiency
ROE?
S&P
3
-44.4%WEAK▾
ROA?
S&P
3
-34.1%WEAK▾
Cash Flow & Enterprise
FCF?$-108810000
Enterprise Value?$261.8M
Fundamentals ratios updated end of day